Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

SUPN – Supernus Pharmaceuticals Inc

Float Short %

9.08

Margin Of Safety %

-8

Put/Call OI Ratio

0.13

EPS Next Q Diff

-0.19

EPS Last/This Y

0.88

EPS This/Next Y

0.21

Price

45.46

Target Price

43.8

Analyst Recom

1.8

Performance Q

38.72

Relative Volume

0.5

Beta

0.78

Ticker: SUPN




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-08-14SUPN42.164.192.003319
2025-08-15SUPN42.694.1858.823318
2025-08-18SUPN42.990.190.13717
2025-08-19SUPN41.990.190.13717
2025-08-20SUPN42.690.190.40725
2025-08-21SUPN43.340.200.08732
2025-08-22SUPN44.860.180.04809
2025-08-25SUPN44.460.160.00875
2025-08-26SUPN44.320.160.00877
2025-08-27SUPN45.090.160.40886
2025-08-28SUPN45.380.160.00890
2025-08-29SUPN45.110.16999.99896
2025-09-02SUPN44.520.160.50897
2025-09-03SUPN44.920.160.00898
2025-09-04SUPN45.430.164.00905
2025-09-05SUPN46.010.140.00889
2025-09-08SUPN45.840.140.00895
2025-09-09SUPN46.020.141.33896
2025-09-10SUPN46.210.141.33896
2025-09-11SUPN46.670.140.00903
2025-09-12SUPN45.460.130.001002
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-08-14SUPN42.15-72.6- 2.25
2025-08-15SUPN42.69-72.6- 2.25
2025-08-18SUPN42.98-72.6- 2.25
2025-08-19SUPN42.00-72.6- 2.25
2025-08-20SUPN42.70-72.6- 2.25
2025-08-21SUPN43.35-72.6- 2.25
2025-08-22SUPN44.88-72.6- 2.25
2025-08-25SUPN44.43-72.6- 2.25
2025-08-26SUPN44.32-72.6- 2.25
2025-08-28SUPN45.37-72.6- 2.25
2025-08-29SUPN45.14-72.6- 2.25
2025-09-02SUPN44.55-72.6- 2.22
2025-09-03SUPN44.92-72.6- 2.22
2025-09-04SUPN45.43-72.6- 2.22
2025-09-05SUPN46.00-72.6- 2.22
2025-09-08SUPN45.82-73.9- 2.22
2025-09-09SUPN46.03-73.9- 2.22
2025-09-10SUPN46.22-73.9- 2.22
2025-09-11SUPN46.66-73.9- 2.22
2025-09-12SUPN45.46-73.9- 2.22
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-08-14SUPN-4.64-0.809.55
2025-08-15SUPN-4.64-0.809.55
2025-08-18SUPN-4.88-2.329.55
2025-08-19SUPN-5.05-2.329.60
2025-08-20SUPN-4.62-2.329.60
2025-08-21SUPN-4.62-2.329.60
2025-08-22SUPN-4.62-2.329.60
2025-08-25SUPN-4.590.459.60
2025-08-26SUPN-5.030.459.60
2025-08-27SUPN-5.030.458.88
2025-08-28SUPN-5.480.458.88
2025-08-29SUPN-6.560.458.88
2025-09-02SUPN-6.560.538.88
2025-09-03SUPN-6.580.538.88
2025-09-04SUPN-6.580.538.88
2025-09-05SUPN-6.580.538.89
2025-09-08SUPN-8.050.578.89
2025-09-09SUPN-8.220.578.89
2025-09-10SUPN-8.220.578.89
2025-09-11SUPN-8.220.579.08
2025-09-12SUPN-8.220.579.08
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.78

Avg. EPS Est. Current Quarter

0.29

Avg. EPS Est. Next Quarter

0.59

Insider Transactions

-8.22

Institutional Transactions

0.57

Beta

0.78

Average Sales Estimate Current Quarter

175

Average Sales Estimate Next Quarter

198

Fair Value

41.73

Quality Score

68

Growth Score

89

Sentiment Score

83

Actual DrawDown %

2.8

Max Drawdown 5-Year %

-45.9

Target Price

43.8

P/E

39.73

Forward P/E

18.66

PEG

5.91

P/S

3.83

P/B

2.4

P/Free Cash Flow

13.71

EPS

1.14

Average EPS Est. Cur. Y​

2.22

EPS Next Y. (Est.)

2.44

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

9.7

Relative Volume

0.5

Return on Equity vs Sector %

-18.8

Return on Equity vs Industry %

-1.7

EPS 1 7Days Diff

EPS 1 30Days Diff

0.18

EBIT Estimation

Supernus Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 674
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
stock quote shares SUPN – Supernus Pharmaceuticals Inc Stock Price stock today
news today SUPN – Supernus Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch SUPN – Supernus Pharmaceuticals Inc yahoo finance google finance
stock history SUPN – Supernus Pharmaceuticals Inc invest stock market
stock prices SUPN premarket after hours
ticker SUPN fair value insiders trading

OGI – OrganiGram Holdings Inc.

Float Short %

6.12

Margin Of Safety %

Put/Call OI Ratio

0.03

EPS Next Q Diff

0.01

EPS Last/This Y

EPS This/Next Y

-0.04

Price

1.65

Target Price

2.18

Analyst Recom

1.5

Performance Q

12.93

Relative Volume

0.54

Beta

1.46

Ticker: OGI




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-08-14OGI1.5550.030.0013557
2025-08-15OGI1.430.020.0213946
2025-08-18OGI1.530.020.0112430
2025-08-19OGI1.5150.020.0112572
2025-08-20OGI1.510.020.0012615
2025-08-21OGI1.5650.020.0012670
2025-08-22OGI1.5950.020.0012771
2025-08-25OGI1.640.020.0013277
2025-08-26OGI1.6450.020.0513551
2025-08-27OGI1.670.020.0013936
2025-08-28OGI1.730.020.0614105
2025-08-29OGI1.7250.030.0315280
2025-09-02OGI1.6450.030.0115594
2025-09-03OGI1.610.030.0315864
2025-09-04OGI1.610.030.0015889
2025-09-05OGI1.650.030.0015978
2025-09-08OGI1.650.030.0016014
2025-09-09OGI1.6350.030.0016158
2025-09-10OGI1.650.030.0116489
2025-09-11OGI1.640.030.0016509
2025-09-12OGI1.650.030.0016460
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-08-14OGI1.55- - 0.07
2025-08-15OGI1.43- - 0.05
2025-08-18OGI1.52- - 0.05
2025-08-19OGI1.52- - 0.05
2025-08-20OGI1.50- - 0.05
2025-08-21OGI1.57- - 0.05
2025-08-22OGI1.6093.1- 0.05
2025-08-25OGI1.6493.1- 0.05
2025-08-26OGI1.6593.1- 0.05
2025-08-28OGI1.7393.1- 0.05
2025-08-29OGI1.7393.1- 0.05
2025-09-02OGI1.6493.1- 0.05
2025-09-03OGI1.6293.1- 0.05
2025-09-04OGI1.6193.1- 0.05
2025-09-05OGI1.6593.1- 0.05
2025-09-08OGI1.6493.1- 0.05
2025-09-09OGI1.6393.1- 0.05
2025-09-10OGI1.6593.1- 0.05
2025-09-11OGI1.6693.1- 0.05
2025-09-12OGI1.6593.1- 0.05
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-08-14OGI0.00-34.776.22
2025-08-15OGI0.00-34.776.22
2025-08-18OGI0.00-35.375.96
2025-08-19OGI0.00-35.375.96
2025-08-20OGI0.00-35.375.96
2025-08-21OGI0.00-35.375.96
2025-08-22OGI0.00-35.375.96
2025-08-25OGI0.00-25.955.96
2025-08-26OGI0.00-25.955.96
2025-08-27OGI0.00-25.955.96
2025-08-28OGI0.00-25.955.96
2025-08-29OGI0.00-25.955.96
2025-09-02OGI0.00-25.996.14
2025-09-03OGI0.00-25.996.14
2025-09-04OGI0.00-25.996.14
2025-09-05OGI0.00-25.996.14
2025-09-08OGI0.00-25.806.14
2025-09-09OGI0.00-25.806.14
2025-09-10OGI0.00-25.806.14
2025-09-11OGI0.00-25.806.12
2025-09-12OGI0.00-25.806.12
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.03

Avg. EPS Est. Current Quarter

-0.01

Avg. EPS Est. Next Quarter

-0.02

Insider Transactions

Institutional Transactions

-25.8

Beta

1.46

Average Sales Estimate Current Quarter

73

Average Sales Estimate Next Quarter

69

Fair Value

Quality Score

47

Growth Score

45

Sentiment Score

13

Actual DrawDown %

93.6

Max Drawdown 5-Year %

-96.3

Target Price

2.18

P/E

255.38

Forward P/E

457.3

PEG

P/S

1.39

P/B

0.79

P/Free Cash Flow

EPS

0.01

Average EPS Est. Cur. Y​

0.05

EPS Next Y. (Est.)

0.01

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

2.9

Relative Volume

0.54

Return on Equity vs Sector %

-22.9

Return on Equity vs Industry %

-5.8

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.02

EBIT Estimation

Organigram Global Inc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1178
Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings and dried flowers to other licensed producers. It sells cannabis products to wholesale and retail channels in the recreational and medical cannabis regimes, as well as through online. Organigram Global Inc. was formerly known as Organigram Holdings Inc. and changed its name to Organigram Global Inc. in March 2025. The company was incorporated in 2010 and is headquartered in Toronto, Canada.
stock quote shares OGI – OrganiGram Holdings Inc. Stock Price stock today
news today OGI – OrganiGram Holdings Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch OGI – OrganiGram Holdings Inc. yahoo finance google finance
stock history OGI – OrganiGram Holdings Inc. invest stock market
stock prices OGI premarket after hours
ticker OGI fair value insiders trading

MURA – Mural Oncology plc

Float Short %

4.8

Margin Of Safety %

Put/Call OI Ratio

0.28

EPS Next Q Diff

1.4

EPS Last/This Y

1.92

EPS This/Next Y

3.88

Price

2.08

Target Price

6

Analyst Recom

2

Performance Q

-17.79

Relative Volume

0.31

Beta

3.02

Ticker: MURA




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-08-14MURA1.780.730.0031967
2025-08-15MURA1.770.710.0932668
2025-08-18MURA1.830.680.0332947
2025-08-19MURA1.8050.660.0033758
2025-08-20MURA2.0850.650.1034011
2025-08-21MURA2.070.290.1230734
2025-08-22MURA2.080.280.0130458
2025-08-25MURA2.060.280.0130458
2025-08-26MURA2.060.28999.9930481
2025-08-27MURA2.070.280.0030490
2025-08-28MURA2.080.280.0030505
2025-08-29MURA2.060.280.0030505
2025-09-02MURA2.080.280.0030510
2025-09-03MURA2.080.280.0030510
2025-09-04MURA2.080.280.0030510
2025-09-05MURA2.080.280.0030510
2025-09-08MURA2.080.280.0030510
2025-09-09MURA2.080.280.0030510
2025-09-10MURA2.070.280.0030510
2025-09-11MURA2.070.280.0030510
2025-09-12MURA2.080.280.0030510
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-08-14MURA1.77- - -5.66
2025-08-15MURA1.77- - -5.66
2025-08-18MURA1.83- - -5.66
2025-08-19MURA1.8068.5- -5.66
2025-08-20MURA2.0968.5- -5.66
2025-08-21MURA2.0868.5- -5.66
2025-08-22MURA2.0868.5- -5.66
2025-08-25MURA2.0768.5- -5.66
2025-08-26MURA2.0668.5- -5.66
2025-08-28MURA2.0768.5- -5.66
2025-08-29MURA2.0768.5- -5.66
2025-09-02MURA2.0868.5- -5.66
2025-09-03MURA2.0868.5- -5.66
2025-09-04MURA2.0868.5- -5.66
2025-09-05MURA2.0768.5- -5.66
2025-09-08MURA2.0768.5- -5.66
2025-09-09MURA2.0868.5- -5.66
2025-09-10MURA2.0768.5- -5.66
2025-09-11MURA2.0768.5- -5.66
2025-09-12MURA2.0868.5- -5.66
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-08-14MURA-0.7923.472.01
2025-08-15MURA-0.7923.472.01
2025-08-18MURA-0.7929.242.01
2025-08-19MURA-0.7929.242.00
2025-08-20MURA-0.8029.242.00
2025-08-21MURA-0.8029.242.00
2025-08-22MURA-0.8029.242.00
2025-08-25MURA-0.80-2.592.00
2025-08-26MURA-0.52-2.592.00
2025-08-27MURA-0.52-2.591.64
2025-08-28MURA-0.52-2.591.64
2025-08-29MURA-0.52-2.591.64
2025-09-02MURA-0.52-2.591.64
2025-09-03MURA-0.52-2.591.64
2025-09-04MURA-0.52-2.591.64
2025-09-05MURA-0.52-2.591.64
2025-09-08MURA-0.37-2.591.64
2025-09-09MURA-0.37-2.591.64
2025-09-10MURA-0.37-2.591.64
2025-09-11MURA-0.37-2.594.80
2025-09-12MURA-0.37-2.594.80
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-1.77

Avg. EPS Est. Current Quarter

-0.59

Avg. EPS Est. Next Quarter

-0.37

Insider Transactions

-0.37

Institutional Transactions

-2.59

Beta

3.02

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

3

Growth Score

Sentiment Score

57

Actual DrawDown %

87.8

Max Drawdown 5-Year %

Target Price

6

P/E

Forward P/E

PEG

P/S

P/B

0.61

P/Free Cash Flow

EPS

-8.58

Average EPS Est. Cur. Y​

-5.66

EPS Next Y. (Est.)

-1.77

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.31

Return on Equity vs Sector %

-275.2

Return on Equity vs Industry %

-262.1

EPS 1 7Days Diff

EPS 1 30Days Diff

-2.28

EBIT Estimation

Mural Oncology plc
Sector: Healthcare
Industry: Biotechnology
Employees: 116
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
stock quote shares MURA – Mural Oncology plc Stock Price stock today
news today MURA – Mural Oncology plc stock forecast ,stock prediction 2023 2024 2025
marketwatch MURA – Mural Oncology plc yahoo finance google finance
stock history MURA – Mural Oncology plc invest stock market
stock prices MURA premarket after hours
ticker MURA fair value insiders trading

EVOK – Evoke Pharma Inc

Float Short %

7.63

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

0.85

EPS This/Next Y

2.6

Price

5.2

Target Price

18

Analyst Recom

1

Performance Q

75.25

Relative Volume

0.01

Beta

-0.09

Ticker: EVOK




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-08-14EVOK5.12N/AN/A0
2025-08-15EVOK5.0983N/AN/A0
2025-08-18EVOK5.88N/AN/A0
2025-08-19EVOK6.15N/AN/A0
2025-08-20EVOK5.8607N/AN/A0
2025-08-21EVOK6.33N/AN/A0
2025-08-22EVOK5.51N/AN/A0
2025-08-25EVOK5.22N/AN/A0
2025-08-26EVOK5.46N/AN/A0
2025-08-27EVOK5.515N/AN/A0
2025-08-28EVOK5.389N/AN/A0
2025-08-29EVOK5.44N/AN/A0
2025-09-02EVOK5.16N/AN/A0
2025-09-03EVOK5.34N/AN/A0
2025-09-04EVOK5.26N/AN/A0
2025-09-05EVOK5.25N/AN/A0
2025-09-08EVOK5.21N/AN/A0
2025-09-09EVOK5.25N/AN/A0
2025-09-10EVOK5.11N/AN/A0
2025-09-11EVOK5.18N/AN/A0
2025-09-12EVOK5.2N/AN/A0
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-08-14EVOK5.1367.7- -1.01
2025-08-15EVOK5.1067.7- -1.01
2025-08-18EVOK5.8667.7- 0.00
2025-08-19EVOK6.1367.7- 0.00
2025-08-20EVOK5.8667.7- 0.00
2025-08-21EVOK6.2667.7- 0.00
2025-08-22EVOK5.5652.1- -1.96
2025-08-25EVOK5.2252.1- -1.96
2025-08-26EVOK5.4152.1- -1.96
2025-08-28EVOK5.2952.1- -1.96
2025-08-29EVOK5.4852.1- -1.96
2025-09-02EVOK5.1652.1- -1.96
2025-09-03EVOK5.2252.1- -1.96
2025-09-04EVOK5.3052.1- -1.96
2025-09-05EVOK5.2152.1- -1.96
2025-09-08EVOK5.2052.1- -1.96
2025-09-09EVOK5.2152.1- -1.96
2025-09-10EVOK5.1252.1- -1.96
2025-09-11EVOK5.1852.1- -1.96
2025-09-12EVOK5.2052.1- -1.96
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-08-14EVOK0.0042.363.74
2025-08-15EVOK0.0042.363.74
2025-08-18EVOK0.0040.353.59
2025-08-19EVOK0.0040.353.59
2025-08-20EVOK0.0040.353.59
2025-08-21EVOK0.0040.353.59
2025-08-22EVOK0.0040.353.59
2025-08-25EVOK0.00-13.023.59
2025-08-26EVOK0.00-13.023.59
2025-08-27EVOK0.00-13.024.25
2025-08-28EVOK0.00-13.024.25
2025-08-29EVOK0.00-13.024.25
2025-09-02EVOK0.00-13.024.25
2025-09-03EVOK0.00-13.024.25
2025-09-04EVOK0.00-13.024.25
2025-09-05EVOK0.00-13.024.25
2025-09-08EVOK0.00-13.884.25
2025-09-09EVOK0.00-13.884.25
2025-09-10EVOK0.00-13.884.25
2025-09-11EVOK0.00-13.887.63
2025-09-12EVOK0.00-13.887.63
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.45

Avg. EPS Est. Next Quarter

-0.39

Insider Transactions

Institutional Transactions

-13.88

Beta

-0.09

Average Sales Estimate Current Quarter

4

Average Sales Estimate Next Quarter

4

Fair Value

Quality Score

36

Growth Score

39

Sentiment Score

34

Actual DrawDown %

99.3

Max Drawdown 5-Year %

-99.7

Target Price

18

P/E

Forward P/E

8.08

PEG

P/S

0.63

P/B

1.76

P/Free Cash Flow

EPS

-2.87

Average EPS Est. Cur. Y​

-1.96

EPS Next Y. (Est.)

0.64

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-42.07

Relative Volume

0.01

Return on Equity vs Sector %

-147.9

Return on Equity vs Industry %

-130.8

EPS 1 7Days Diff

-1

EPS 1 30Days Diff

-0.95

EBIT Estimation

Evoke Pharma, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 3
Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is based in Solana Beach, California.
stock quote shares EVOK – Evoke Pharma Inc Stock Price stock today
news today EVOK – Evoke Pharma Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch EVOK – Evoke Pharma Inc yahoo finance google finance
stock history EVOK – Evoke Pharma Inc invest stock market
stock prices EVOK premarket after hours
ticker EVOK fair value insiders trading

AMPH – Amphastar Pharmaceuticals Inc

Float Short %

12.14

Margin Of Safety %

18

Put/Call OI Ratio

0.23

EPS Next Q Diff

0.16

EPS Last/This Y

0.03

EPS This/Next Y

0.47

Price

28.06

Target Price

32.67

Analyst Recom

2

Performance Q

6.13

Relative Volume

0.52

Beta

0.78

Ticker: AMPH




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-08-14AMPH30.330.230.001368
2025-08-15AMPH29.840.171.171725
2025-08-18AMPH29.760.210.421295
2025-08-19AMPH30.320.220.001370
2025-08-20AMPH29.60.220.091386
2025-08-21AMPH29.670.220.001386
2025-08-22AMPH30.490.210.001391
2025-08-25AMPH29.830.210.081399
2025-08-26AMPH30.370.210.171406
2025-08-27AMPH30.490.210.001420
2025-08-28AMPH30.250.210.001431
2025-08-29AMPH30.630.19999.991413
2025-09-02AMPH30.810.220.051453
2025-09-03AMPH29.390.220.031450
2025-09-04AMPH29.190.220.001453
2025-09-05AMPH29.470.220.001459
2025-09-08AMPH29.310.22999.991461
2025-09-09AMPH29.350.230.751470
2025-09-10AMPH28.380.231.501475
2025-09-11AMPH28.690.230.671475
2025-09-12AMPH28.050.230.291479
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-08-14AMPH30.22-9.9- 3.32
2025-08-15AMPH29.83-9.9- 3.32
2025-08-18AMPH29.77-9.9- 3.32
2025-08-19AMPH30.33-12.0- 3.30
2025-08-20AMPH29.60-12.0- 3.30
2025-08-21AMPH29.67-12.0- 3.30
2025-08-22AMPH30.50-12.0- 3.30
2025-08-25AMPH29.84-12.0- 3.30
2025-08-26AMPH30.34-12.0- 3.30
2025-08-28AMPH30.26-11.3- 3.32
2025-08-29AMPH30.61-11.3- 3.32
2025-09-02AMPH30.81-11.3- 3.32
2025-09-03AMPH29.40-11.3- 3.32
2025-09-04AMPH29.22-11.3- 3.32
2025-09-05AMPH29.42-11.3- 3.32
2025-09-08AMPH29.26-11.3- 3.32
2025-09-09AMPH29.28-11.3- 3.32
2025-09-10AMPH28.40-11.3- 3.32
2025-09-11AMPH28.68-11.3- 3.32
2025-09-12AMPH28.06-11.3- 3.32
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-08-14AMPH-0.06-6.2911.80
2025-08-15AMPH-0.06-6.2911.80
2025-08-18AMPH-0.06-4.1211.80
2025-08-19AMPH-0.06-4.1211.76
2025-08-20AMPH-0.06-4.1211.76
2025-08-21AMPH-0.06-4.1211.76
2025-08-22AMPH-0.06-4.1211.76
2025-08-25AMPH-0.06-1.7311.76
2025-08-26AMPH-0.06-1.7311.76
2025-08-27AMPH-0.06-1.7312.08
2025-08-28AMPH-0.06-1.7312.08
2025-08-29AMPH-0.06-1.7312.08
2025-09-02AMPH-0.06-1.7012.08
2025-09-03AMPH-0.07-1.7012.08
2025-09-04AMPH-0.07-1.7012.08
2025-09-05AMPH-0.07-1.7012.08
2025-09-08AMPH-0.02-1.7412.08
2025-09-09AMPH-0.02-1.7412.08
2025-09-10AMPH-0.02-1.7412.08
2025-09-11AMPH-0.02-1.7412.14
2025-09-12AMPH-0.02-1.7412.14
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.75

Avg. EPS Est. Current Quarter

0.85

Avg. EPS Est. Next Quarter

0.91

Insider Transactions

-0.02

Institutional Transactions

-1.74

Beta

0.78

Average Sales Estimate Current Quarter

186

Average Sales Estimate Next Quarter

195

Fair Value

33.21

Quality Score

87

Growth Score

92

Sentiment Score

35

Actual DrawDown %

58.5

Max Drawdown 5-Year %

-68.3

Target Price

32.67

P/E

10.51

Forward P/E

7.4

PEG

4.89

P/S

1.81

P/B

1.72

P/Free Cash Flow

11.63

EPS

2.67

Average EPS Est. Cur. Y​

3.32

EPS Next Y. (Est.)

3.79

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

18.64

Relative Volume

0.52

Return on Equity vs Sector %

-7.1

Return on Equity vs Industry %

10

EPS 1 7Days Diff

EPS 1 30Days Diff

0.19

EBIT Estimation

Amphastar Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 2028
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
stock quote shares AMPH – Amphastar Pharmaceuticals Inc Stock Price stock today
news today AMPH – Amphastar Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch AMPH – Amphastar Pharmaceuticals Inc yahoo finance google finance
stock history AMPH – Amphastar Pharmaceuticals Inc invest stock market
stock prices AMPH premarket after hours
ticker AMPH fair value insiders trading

ALKS – Alkermes plc

Float Short %

8.28

Margin Of Safety %

1

Put/Call OI Ratio

0.88

EPS Next Q Diff

-0.12

EPS Last/This Y

-0.47

EPS This/Next Y

-0.22

Price

26.96

Target Price

41.59

Analyst Recom

1.65

Performance Q

-12.38

Relative Volume

1.27

Beta

0.53

Ticker: ALKS




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-08-14ALKS28.260.610.2627322
2025-08-15ALKS29.060.600.3027952
2025-08-18ALKS28.110.471.4415206
2025-08-19ALKS28.850.500.3015719
2025-08-20ALKS28.980.503.0915817
2025-08-21ALKS29.070.555.6316544
2025-08-22ALKS29.760.560.2416718
2025-08-25ALKS28.990.553.3916959
2025-08-26ALKS28.990.60144.8017897
2025-08-27ALKS29.250.650.3818511
2025-08-28ALKS28.930.650.7418522
2025-08-29ALKS28.970.673.0018667
2025-09-02ALKS29.420.687.0318897
2025-09-03ALKS29.960.701.0619237
2025-09-04ALKS28.930.801.1222993
2025-09-05ALKS29.950.812.6824379
2025-09-08ALKS28.440.861.1125821
2025-09-09ALKS27.830.757.0731681
2025-09-10ALKS26.910.881.3034130
2025-09-11ALKS27.720.880.2234160
2025-09-12ALKS26.970.881.5834238
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-08-14ALKS28.26-47.1-110.21.73
2025-08-15ALKS29.06-47.1-94.01.73
2025-08-18ALKS28.11-47.1-117.91.73
2025-08-19ALKS28.85-47.1-94.81.73
2025-08-20ALKS28.98-47.1-103.41.73
2025-08-21ALKS29.07-47.1-103.81.73
2025-08-22ALKS29.76-47.1-95.61.73
2025-08-25ALKS28.99-47.1-115.21.73
2025-08-26ALKS28.98-47.1-105.41.73
2025-08-28ALKS28.93-47.1-109.51.73
2025-08-29ALKS28.96-47.1-104.81.73
2025-09-02ALKS29.40-47.1-99.31.73
2025-09-03ALKS30.01-47.1-88.61.73
2025-09-04ALKS28.92-47.1-111.51.73
2025-09-05ALKS29.94-47.1-82.71.73
2025-09-08ALKS28.45-47.4-116.91.70
2025-09-09ALKS27.84-47.1-105.71.73
2025-09-10ALKS26.93-47.3-110.51.75
2025-09-11ALKS27.71-47.3-85.11.75
2025-09-12ALKS26.96-47.3-108.11.75
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-08-14ALKS-8.872.368.56
2025-08-15ALKS-0.372.368.56
2025-08-18ALKS-0.37-1.518.60
2025-08-19ALKS-0.31-1.518.60
2025-08-20ALKS-0.31-1.518.60
2025-08-21ALKS-0.28-1.518.60
2025-08-22ALKS-0.28-1.518.60
2025-08-25ALKS-0.28-2.048.60
2025-08-26ALKS-0.20-2.048.60
2025-08-27ALKS-0.20-2.048.59
2025-08-28ALKS-0.20-2.048.59
2025-08-29ALKS-0.20-2.048.59
2025-09-02ALKS-0.15-2.038.59
2025-09-03ALKS-0.15-2.038.59
2025-09-04ALKS-0.15-2.038.59
2025-09-05ALKS-0.15-2.038.59
2025-09-08ALKS-0.15-2.058.59
2025-09-09ALKS-0.15-2.058.59
2025-09-10ALKS-0.15-2.058.59
2025-09-11ALKS-0.15-2.058.28
2025-09-12ALKS-0.15-2.058.28
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.52

Avg. EPS Est. Current Quarter

0.38

Avg. EPS Est. Next Quarter

0.4

Insider Transactions

-0.15

Institutional Transactions

-2.05

Beta

0.53

Average Sales Estimate Current Quarter

355

Average Sales Estimate Next Quarter

366

Fair Value

27.32

Quality Score

99

Growth Score

40

Sentiment Score

5

Actual DrawDown %

26

Max Drawdown 5-Year %

-33.2

Target Price

41.59

P/E

12.95

Forward P/E

17.21

PEG

P/S

2.96

P/B

2.74

P/Free Cash Flow

9.28

EPS

2.08

Average EPS Est. Cur. Y​

1.75

EPS Next Y. (Est.)

1.53

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

23.15

Relative Volume

1.27

Return on Equity vs Sector %

-3.4

Return on Equity vs Industry %

13.7

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

-108.1
Alkermes plc
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1800
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
stock quote shares ALKS – Alkermes plc Stock Price stock today
news today ALKS – Alkermes plc stock forecast ,stock prediction 2023 2024 2025
marketwatch ALKS – Alkermes plc yahoo finance google finance
stock history ALKS – Alkermes plc invest stock market
stock prices ALKS premarket after hours
ticker ALKS fair value insiders trading
No more stocks to show